Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal colistin inhalation with Pari-Sinus nebulizer in cystic fibrosis patients colonized with Pseudomonas aeruginosa in upper airways
2008-007877-19Phase 2Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- May 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of colistin in cystic fibrosis (CF) and Pseudomonas aeruginosa upper respiratory tract infection, sponsored by Friedrich Schiller University Jena. Primary endpoints: Reduction of Pseudomonas aeruginosa in nasal lavage, Reduction of Pseudomonas aeruginosa at maxillary sinus ostium and 1 more. Started May 2009; status: completed.
02
Drugs
colistin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa upper respiratory tract infection
Beyond the preview
Go deeper on 2008-007877-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007877-19.